EVALUATING SUBJECT MATTER ELIGIBILITY UNDER 35 U. S. C

Slides:



Advertisements
Similar presentations
In re Bilski Federal Circuit (2008) (en banc) Decided: October 30, 2008 A very SMALL decision on a very BIG issue!
Advertisements

UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the Notes Tab. 35 USC 112 (f)*: Identifying Limitations.
Michael P. Woodward Supervisory Patent Examiner, Art Unit 1631 (703) Bioinformatics & §101
Second level — Third level Fourth level »Fifth level CLS Bank And Its Aftermath Presented By: Joseph A. Calvaruso Orrick, Herrington & Sutcliffe LLP ©
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Recent Cases on Patentable Subject Matter and Patent Exhaustion Mojdeh Bahar, J.D., M.A. Chief, Cancer Branch Office of Technology Transfer National Institutes.
1 Bioinformatics Practice Considerations October 20, 2011 Ling Zhong, Ph.D.
PATENTABLE SUBJECTS IN THE INTERNET OF THINGS ALICIA SHAH.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Memorandum - 35 U.S.C. 112, Second and Sixth Paragraphs Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
AIPLA Biotechnology Committee Webinar: Mayo v. Prometheus: Did the Bell Toll for Personalized Medicine Patents? Prof. Joshua D. Sarnoff DePaul U. College.
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
* Statements of fact and opinions expressed are those of the speaker individually and are not the opinion or position of Research In Motion Limited or.
Restriction Practice for Genus Claims Species Claims Linking Claims and Markush Claims Julie Burke QAS/PM TC1600.
In re Bilski (Fed Cir. 2008) Patentable subject matter In re Bilski (Fed Cir. 2008) Patentable subject matter December 2, 2008 John King Ron Schoenbaum.
1 TC 1600 Subject Matter Eligibility Under 35 USC § 101 Andrew Wang SPE 1631 (571)
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
Medical Device Partnership: USPTO Interim Eligibility Guidance Michael Cygan, USPTO June 2, 2015.
Examiner Guidelines After Alice Corp. August 21, 2014 How Much “More” is “Significantly More”?
Examining Functional Claim Limitations: Focus on Computer/Software-related Claims
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
35 USC 101 Update Business Methods Partnership Meeting, Spring 2008 by Robert Weinhardt Business Practice Specialist, Technology Center 3600
Biotechnology/Chemical/Pharmaceutical Customer Partnership: Recent Examiner Training and Developments Under 35 USC § 101 Drew Hirshfeld Deputy Commissioner.
Are software patents “... anything under the sun made by man...”? © 2006 Peter S. Menell Professor Peter S. Menell Boalt Hall School of Law Berkeley Center.
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Patent Prosecution Luncheon March White House Patent Reform: Executive Actions Draft rule to ensure patent owners accurately record and regularly.
Subject Matter Patentability for Bioinformatics Patent Applications Principles & Practice Gregory L. Maurer Klarquist Sparkman, LLP AIPLA Spring Meeting.
California :: Delaware :: Florida :: New Jersey :: New York :: Pennsylvania :: Virginia :: Washington, DC :: Advice for Drafting.
1 P atent S ubject M atter E ligibility – Patentable Subject Matter in US Practice Dr. Hezy Saado, Patent Attorney,
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
The student will demonstrate an understanding of how scientific inquiry and technological design, including mathematical analysis, can be used appropriately.
Post-Prometheus Interim Examination Guidelines Daphne Lainson Smart & Biggar AIPLA 1.
11 PATENT LAW Randy Canis CLASS 15 Case Law Update.
Post-Bilski Patent Prosecution IP Osgoode March 13, 2009 Bob Nakano McCarthy Tétrault LLP.
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
Josiah Hernandez Patentability Requirements. Useful Having utilitarian or commercial value Novel No one else has done it before If someone has done it.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
Josiah Hernandez What can be Patented. What can be patented A patent is granted to anyone who “invents or discovers any new and useful process, machine,
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
Computer Software-Related Inventions Patent Eligibility in Japan Dr. Shoichi Okuyama Okuyama & Sasajima October 22, 2015 AIPLA Annual Meeting.
1. 35 USC § 101: Statutory Requirements and Four Categories of Invention August 2015 Office of Patent Legal Administration United States Patent and Trademark.
INTERIM GUIDELINES FOR PATENT SUBJECT MATTER ELIGIBILITY ARDIN MARSCHEL SPE AU 1631 (571)
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
Mayo v. Prometheus Labs – The Backdrop June 12, 2012 © 2012, all rights reserved.
Patentable Subject Matter Donald M. Cameron. 2 Patents: The Bargain Public: gets use of invention after patent expires Inventor/Owner: gets limited monopoly.
Double Patenting Deborah Reynolds SPE Art Unit 1632 Detailee, TC1600 Practice Specialist
July 2015 Update to the Interim Eligibility Guidance: Abstract Idea Example Workshop II 1.
Interim Guidance on Patent Subject Matter Eligibility Raul Tamayo, USPTO July 13, 2015.
A Madness to the Method? The Future of Method Patents After Bilski Brian S. Mudge July 19, 2010.
Jody Blanke, Professor Computer Information Systems and Law 1.
What did Enfish V Microsoft do? Dr. Sinai Yarus©
Alexandria, Virginia July 21, 2014
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
ChIPs Global Summit, September 15, 2016
Global Innovation Management Workout on Writing a Patent
Comparing subject matter eligibility in us and eu
Stem Cells Peter Paras, Jr.
Subject Matter Eligibility
A tutorial and update on patentable subject matter
Examination Practice in Applications Presenting “Reach-Through Claims”
Presentation transcript:

EVALUATING SUBJECT MATTER ELIGIBILITY UNDER 35 U. S. C EVALUATING SUBJECT MATTER ELIGIBILITY UNDER 35 U.S.C. §101 Marjorie Moran Supervisory Patent Examiner Art Unit 1631

35 USC 101 Relevant Decisions In re Nuijten, 84 USPQ2d 1495 (Fed. Cir. 2007) In re Comiskey, 89 USPQ2d 1641 (Fed. Cir. 2009) In re Bilski, 88 USPQ2d 1385 (Fed. Cir. 2008) Prometheus Laboratories Inc. v. Mayo Collaborative Services, 92 USPQ2d 1075 (Fed. Cir. 2009)

SUMMARY The Instructions supersede previous guidance on subject matter eligibility that conflicts with the Instructions, including MPEP 2106(IV), 2106.01 and 2106.02, as of 8/24/09. – To determine subject matter eligibility, follow the “Interim Examination Instructions for Evaluating Subject Matter Eligibility Under 35 U.S.C. § 101”. See: http://www.uspto.gov/web/offices/pac/dapp/opla/2009-08-25_interim_101_instructions.pdf. • Product claims are evaluated to determine if the claim is wholly directed to a judicial exception. – Functional/nonfunctional descriptive material (FDM/NFDM) is evaluated for patentable distinction over the prior art. See MPEP 2112.01(III). • All process (method) claims are evaluated with the M-or-T test.

35 USC 101 CLAIM EVALUATION: STEP 1 • Determine whether the claim is directed to one of the four patent-eligible subject matter categories: – Process, Machine, Manufacture, Composition of Matter If not in one of the four categories, the claim is not eligible. – Examples of claims that are not eligible are claims directed to: Transitory signals per se, humans per se, a company per se, or a set of instructions per se (such as a game or software per se)

35 USC 101 CLAIM EVALUATION: STEP 2 • A claim satisfying Step 1 is subject-matter eligible under 101 unless it wholly embraces a judicially recognized exception. • Does the claim wholly embrace a judicially recognized exception? – Abstract Idea – Law of Nature – Natural Phenomena – The exceptions also include, for example: • Mental Processes • Mathematical Algorithms • Scientific Principles If the claim is directed to a judicial exception itself, it is NOT eligible. A particular practical application of a judicial exception IS eligible.

35 USC 101 PRODUCT CLAIM ANALYSIS • Begin with the broadest reasonable interpretation (BRI) of the claim in view of the specification consistent with the interpretation those skilled in the art would reach. MPEP 2111 • Product Focus: – Does the claim meet definitions of machine, manufacture or composition of matter? – Is there a judicial exception recited in the claim?

COMPUTER-READABLE MEDIA Additional information The functional/non-functional distinction is not an inquiry under 101. The 101 inquiry is whether a claim directed to one of the four statutory categories is wholly directed to a judicial exception. • A tangible medium including a computer program should be evaluated to determine if there is a functional relationship between the computer program and the medium for purposes of distinguishing over prior art, not for subject matter eligibility.

SUBJECT MATTER ELIGIBILITY TEST PRODUCT FLOWCHART IS THE CLAIM TO A PROCESS, MACHINE, MANUFACTURE OR COMPOSITION OF MATTER? NO To M1 YES GO TO PROCESS FLOWCHART TO TEST FOR PRACTICAL APPLICATION YES IS IT A PROCESS CLAIM? NO DOES THE CLAIM RECITE AN ABSTRACT IDEA, LAW OF NATURE OR NATURAL PHENOMENON (JUDICIALLY RECOGNIZED EXCEPTIONS)? NO YES IS THE CLAIM AS A WHOLE DIRECTED TO A PRACTICAL APPLICATION OF THE ABSTRCAT IDEA, LAW OF NATURE OR NATURAL PHENOMENON? A MAN-MADE TANGIBLE EMBODIMENT WITH A REAL WORLD USE IS EVIDENCE OF A PRACTICAL APPLICATION. NO YES DOES THE CLAIM COVER SUBSTANTIALLY ALL PRACTICAL APPLICATIONS OF THE EXCEPTION? (THE LIMITED OCCURRENCE OF PREMEPTION) MATHAMTICAL SUBJECT MATTER STANDING ALONE, SUCH THAT USE OF THAT SUBJECT MATTER IN OTHER WAYS IS PRECLUDED, IS EVIDENCE OF PREEMPTION NO YES CLAIM QUALIFIES AS PATENT ELIGIBLE SUBJECT MATTER CLAIM IS NOT ELIGIBLE SUBJECT MATTER

a receiving module which receives peptide sequence information; Product Example 1 Claim: A computer system for determining similarity of two peptides comprising: a receiving module which receives peptide sequence information; an alignment module for aligning received peptide sequences; and a calculating module for calculating a degree of similarity between the aligned peptide sequences. BRI: The claim is directed to series of instructions, or a program per se. The specification discloses a computer, computer readable media, and programs for comparing sequences of peptides. The instructions for the program disclosed in the specification exactly reflect the claimed “modules.” Under the broadest reasonable interpretation, in view of the specification and the general knowledge in the art, the claimed “system” consists of a computer program that may exist apart from a computer or tangible media.

Product Example 1, continued Analysis: The claim is nominally directed to a product; i.e. a computer system. The claim does not recite any structural limitations. In view of the BRI, the claim encompasses a program, per se. Programs per se do not fall into one of the statutory categories of invention. This claim is not patent eligible.

35 U.S.C. § 101 M or T Test and Process Claims A process claim, to be statutory under 35 U.S.C. § 101, must pass the machine or transform test (M or T test), which ensures that the process is limited to a particular practical application. The test ensures that the process is not simply claiming an abstract idea, mental process or substantially all practical uses of (preempting) a law of nature or natural phenomenon.

35 U.S.C. § 101 M or T Test and Process Claims In accordance with the M or T test, the claimed process must: (1) be tied to a particular machine or apparatus (machine-implemented); OR (2) particularly transform a particular article to a different state or thing. A method claim that does not require machine implementation or does not cause a transformation will fail the test and be rejected under 35 U.S.C. § 101. Note that the mere presence of a machine or transformation is not sufficient to pass the M or T test - the tie must be to a particular machine or the particular transformation of a particular article.

SUBJECT MATTER ELIGIBILITY TEST (M-OR-T) FOR PROCESS CLAIMS 1. DETERMINE THAT THE CLAIM IS DIRECTED TO A PROCESS (A METHOD OR SERIES OF ACTS OR STEPS) 2. TEST TO DETERMINE IF PROCESS IS STATUTORY BY USING THE MACHINE OR TRANSFORMATION (M-OR-T) TEST TO DETERMINE WHETHER THE CLAIM IS DIRECTED WHOLLY TO A JUDICIAL EXCEPTION (INELIGIBLE) OR TO A PARTICULAR PRACTICAL APPLICATION OF A JUDICIAL EXCEPTION (ELIGIBLE) USING THE FOLLOWING FLOW CHART: PROCESS FLOWCHART DOES THE CLAIM REQUIRE THAT THE METHOD BE IMPLEMENTED BY A PARTICULAR MACHINE? YES DOES THE USE OF THE PARTICULAR MACHINE IMPOSE A MEANINGFUL LIMIT ON THE CLAIM’S SCOPE? (DOES IT INVOLVE MORE THAN FIELD OF USE LIMITATION?) AND DOES THE USE OF THE MACHINE INVOLVE MORE THAN INSIGNFICANT EXTRA-SOLUTION ACTIVITY? NO DOES THE CLAIM REQUIRE THAT THE METHOD PARTICULARLY TRANSFORM A PARTICULAR ARTICLE? NO NO YES DOES THE TRANSFORMATION IMPOSE A MEANINGFUL LIMIT ON THE CLAIM’S SCOPE? (DOES IT INVOLVE MORE THAN FIELD OF USE LIMITATION?) AND DOES THE TRANSFORMATION INVOLVE MORE THAN INSIGNFICANT EXTRA-SOLUTION ACTIVITY? YES NO YES METHOD IS ELIGIBLE STATUTORY PROCESS CONFIRM M-OR-T TEST: ENSURE CLAIMED METHOD (1) IS NOT SO ABSTRACT AND SWEEPING AS TO HAVE NO REAL WORLD APPLICATION AND (2) DOES NOT PRE=EMPT SUBSTANTIALLY ALL PRACTICAL USES OF A JUDICIAL EXCEPTION METHOD IS NOT ELIGIBLE

Claim: A method of identifying an inhibitor for enzyme X comprising: Process Example 2 Claim: A method of identifying an inhibitor for enzyme X comprising: -providing enzyme X in solution, -contacting enzyme X with at least one substrate and at least one putative inhibitor, and -determining whether the substrate is cleaved. BRI: The method is directed to detecting activity of enzyme X. Under the broadest reasonable interpretation, in view of the specification and the general knowledge in the art, contacting solvated enzyme X with a substrate causes a change in the state of the substrate, through a chemical reaction. The presence of an inhibitor interacts with either the substrate or the enzyme X to change the chemical activity of either the substrate or the enzyme X, thus leading to a change of state of the substrate or the enzyme X.

Process Example 2, continued Analysis: The claim is directed to a method so the machine-or-transformation test is applied. The contacting step involves a transformation whether the substrate is cleaved or not. If the substrate is cleaved, then the substrate is transformed. If the substrate is not cleaved, then either the substrate or the enzyme has undergone a biochemical change and thus a transformation. With respect to the corollaries, the performance of the step of contacting is limited to such actions that result in the transformation of the at least one of the contacted materials. The transformation of the system to a different state through the contacting of the materials is therefore a meaningful limit on the claim. Since the step of contacting is central to the purpose of the claim, which is determining the interaction between the contacted materials, the step of contacting is not merely extrasolution activity. Therefore, the claim passes the transformation prong of the subject matter eligibility analysis. Since the claim is thus subject matter eligible, no further analysis is necessary. This claim is patent eligible.

Process Example 3 Claim: A method of identifying a human sequence homologous to a prokaryotic gene comprising: -contacting the prokaryotic gene with an array of human oligonucleotide sequences, -quantitating the degree of hybridization between the prokaryotic gene and individual locations on the array. BRI: The array comprises sequences on a solid surface. The specification discloses use of a commercially available set of human sequences on a glass chip. Under the broadest reasonable interpretation, in view of the specification and the general knowledge in the art, hybridization is a chemical transformation of the gene and the array. Further, contacting the gene with the array will cause the gene to undergo conformational changes even in the absence of hybridization, and those conformational changes represent a change of state of the gene. The quantitating step could be performed either by inspection or by a specific machine.

Process Example 3, continued Analysis: The claim is directed to a method so the machine-or-transformation test is applied. The claim does not require a specific machine to perform any of the steps in the method so the claim does not pass the machine prong of the inquiry. A step of contacting a nucleic acid with another directly results in a physical transformation of matter either through hybridization or through biochemical changes in the gene. With respect to the corollaries, the performance of the step of contacting is limited to such actions that result in the transformation of the at least one of the contacted materials. The transformation of the system to a different state through the contacting of the materials is therefore a meaningful limit on the claim. Since the step of contacting is central to the purpose of the claim, which is determining the interaction between the contacted materials, the step of contacting is not merely extrasolution activity. This claim is patent eligible.

Process Example 4 A process for plant selection, comprising: -providing a database of plant species; -eliminating a portion of the plant species using at least two criteria to eliminate unsuitable plant species; and -selecting at least one image of the plant species meeting desirable criteria, at least one of said images comprising desirable characteristics of leaf, flower and/or fruit. BRI: The eliminating and selecting steps may be performed by eye by merely viewing images. Although the specification discloses a computerized database and an algorithm for searching the database for plant images which meet specified criteria, the broadest reasonable interpretation of the claim language “providing a database” does not require use of a machine as it could reasonably include providing a book or set of images.

Process Example 4, continued Analysis: The claim is directed to a process so the machine-or-transformation test is applied. Based on the BRI, no step explicitly or inherently requires a machine so the claim does not pass the machine prong of the inquiry. No step requires a transformation of a particular article to a different state or thing so the claim also does not pass the transformation prong of the inquiry. This claim is NOT patent eligible.

Process Example 5 Claim: A method for displaying a three dimensional representation of a structure of a protein comprising: -obtaining three dimensional coordinates for the protein; -determining a three dimensional representation of a structure based on the three dimensional coordinates; and -displaying the three dimensional representation of the protein structure. BRI: Based on the broadest reasonable interpretation, the obtaining step does not require a particular machine or a particular transformation, since the specification teaches obtaining 3D coordinates of peptides and proteins from known and publicly available sources (textbooks and online databases). Therefore the “obtaining” step does not require a transformative step such as protein crystallization or the use of a machine such as an X-ray diffractometer. The displaying step does not require a particular machine, since although the specification discloses use of a commercially available program to display the structure using the 3D coordinates, the claim does not explicitly define or limit the display to a computerized display. Moreover, one of ordinary skill in the art would reasonably understand the displaying step to include displaying the protein structure using a drawing or a model.

Process Example 5, continued Analysis: The claim is directed to a method so the machine-or-transformation test is applied. The broadest reasonable interpretation of the claim is that no step requires a particular machine so the claim does not pass the machine prong of the inquiry. With respect to transformation, the step of obtaining coordinates does not require actually performing crystallization, and in view of the specification, may be interpreted as a step of obtaining data from a table, therefore the claim does not recite a physical transformation of matter. Therefore, there is neither a machine tie nor a transformation required by the claim. The claim is NOT patent eligible.

Process Example 6 Claim: A method for displaying a three dimensional representation of a structure of a protein comprising: -crystallizing the protein; -obtaining three dimensional coordinates from a crystal analysis of the protein; -determining a three dimensional representation of a structure based on the three dimensional coordinates; and -displaying the three dimensional representation of the protein structure. BRI: Crystallizing a protein is a transformation of the protein from a solvated phase to a solid phase, and thus represents a change in state. While 3D coordinates can be obtained from a table for a KNOWN crystal, obtaining 3D coordinates from a “crystal analysis” cannot be performed by inspection, and requires the use of a particular machine to perform this step. The examiner has made this determination by reading the specification, which teaches crystallizing the protein and obtaining 3D coordinates by X-ray diffraction, in view of one having ordinary skill in the art.

Process Example 6, continued Analysis: The claim is directed to a method so the machine-or-transformation test is applied. The step of crystallization necessarily involves a physical transformation of matter. With respect to the corollaries, the performance of the step of “crystallizing the protein” is limited to such actions that result in the transformation of the protein. The transformation of the sample is a therefore a meaningful limit on the claim. The crystallization step is central to the purpose of the claim, displaying the structure of the crystal, and is therefore not merely extrasolution activity. Therefore, the claim passes the transformation prong of the subject matter eligibility analysis. Since the claim is thus subject matter eligible, no further analysis is necessary. This claim is patent eligible.

Questions? Contact information marjorie.moran@uspto.gov 571-272-0720